{
    "nctId": "NCT00264472",
    "briefTitle": "A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors",
    "officialTitle": "A 2-Part Phase 1 Study Evaluating the Safety and Anti-Tumor Activity of ADH300004 (Eniluracil) Administered With 5-Fluorouracil (5-FU), and the Pharmacokinetics of 5-FU Given as: 5.0 mg ADH300004 With Escalating Doses of 5-FU Administered Orally 3 Weeks Out of 4 in Subjects With Refractory Solid Tumors (Part 1); or 5.0 mg ADH300004 With 5 FU Administered Orally as a Split Dose for 3 Weeks Out of 4 in Subjects With Hepatocellular Carcinoma, Non-Small Cell Lung Carcinoma, Gastric Cancer, Cervical Cancer, Prostate Cancer, or Breast Cancer (Part 2) (Adherex Protocol Number AHX-03-104)",
    "overallStatus": "SUSPENDED",
    "conditions": "Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Part 1: To determine the DLTs and MTD of the combination of ADH300004 and 5 FU administered orally in a weekly regimen, for 3 weeks with 1 week rest per cycle, in subjects with incurable solid tumors",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed written informed consent\n* \\> or = 18 years of age\n* Advanced or metastatic solid tumors:\n\nPart 1: Histologically proven advanced or metastatic solid tumors refractory to standard therapy or for which no standard therapy exists\n\nPart 2: Histologically proven advanced and/or metastatic solid tumor of one of the following 6 histologies, that is refractory to standard curative therapy or for which no curative therapy exists: HCC, NSCLC, gastric cancer, cervical cancer, prostate cancer, and breast cancer\n\n* Radiologically documented measurable or evaluable (non-measurable) disease\n* Adequate performance status and organ function, as evidenced by hematologic and biochemical blood testing\n* Willing to not receive fluoropyrimidine containing chemotherapy for 8 weeks after the last dose of ADH300004 in this study\n\nExclusion Criteria:\n\n* Cytotoxic chemotherapy, radiotherapy, or investigational drug within 28 days prior to study entry\n* Non-cytotoxic cancer therapy within 14 days prior to study entry\n* Portal hypertension with bleeding esophageal or gastric varices within the past 3 months\n* Ascites that is refractory to conservative management\n* Inability to take oral medication\n* Active peptic ulcer disease\n* Known hypersensitivity to 5-FU or ADH300004\n* Stroke, major surgery, or other major tissue injury within 30 days before study entry",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}